||Neurocognitive Challenges: What's on Your Mind?
Oral Abstract Session : Track B
||Melbourne Room 2
||24.07.2014, 16:30 - 18:00
Bruce Brew, Australia
Darma Imran, Indonesia
|Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients|
C. Pinnetti1, P. Balestra1, R. Libertone1, P. Lorenzini1, A. Cozzi-Lepri2, A. Ammassari1, M. Ricottini1, M. Plazzi1, S. Menichetti1, V. Tozzi1, A. Antinori1
1National Institute for Infectious Disease, Rome, Italy, 2University College London, London, United Kingdom
|Determining the prevalence of HIV-associated neurocognitive disorder in a high-functioning and optimally treated Australian cohort: implications for international neuroHIV research|
L.A. Cysique1,2, R.K. Heaton3, J. Kamminga4, T. Lane5, T.M. Gates5, D.M. Moore5, E. Hubner1, A. Carr2,6, B.J. Brew2,5
1The University of New South Wales, Neuroscience Research Australia, Randwick, Australia, 2St. Vincent's Hospital Centre for Applied Medical Research, Sydney, Australia, 3The University of California San Diego, HIV Neurobehavioral Research Center, San Diego, United States, 4Neuroscience Research Australia, Randwick, Australia, 5St.Vincent's Hospital, Neurology Department, Sydney, Australia, 6St.Vincent's Hospital, Immunology and Infectious Diseases Department, Sydney, Australia
|Neurocognitive change in the era of HIV combination antiretroviral therapy: a longitudinal CHARTER study|
R. Heaton1, D. Franklin1, R. Deutsch1, S. Letendre1, R. Ellis1, K. Blackstone1, M. Marquine1, S. Woods1, F. Vaida1, J. Atkinson1,2, T. Marcotte1, J. McCutchan1, A. Collier3, C. Marra3, D. Clifford4, B. Gelman5, J. Mc Arthur6, S. Morgello7, D. Simpson7, I. Abramson1, A. Gamst1, C. Fennema-Notestine1, D. Smith1, I. Grant1, the CHARTER Group
1University of California San Diego, La Jolla, United States, 2VA San Diego Healthcare System, San Diego, United States, 3University of Washington, Seattle, United States, 4Washington University St Louis, St Louis, United States, 5University of Texas Medical Branch, Galveston, United States, 6Johns Hopkins University, Baltimore, United States, 7Icahn School of Medicine at Mount Sinai, New York, United States
|High ratios of circulating pro-inflammatory cytokines to anti-inflammatory IL-10 correlate with regional brain atrophy in chronic suppressed HIV infection|
K. Kallianpur1, M. Sakoda2, T. Umaki1, P. Norris3, S. Keating3, J. Barbour2, L. Ndhlovu2, D. Chow1, E. Nakasone2, C. Shikuma1
1University of Hawaii, Dept. of Medicine/Hawaii Center for AIDS, Honolulu, United States, 2University of Hawaii, Honolulu, United States, 3Blood Systems Research Institute/UCSF, San Francisco, United States
|Is mental depression a serious issue among female sex workers? Evidence from Southern India|
S.K. Patel1, N. Saggurti1, S. Pachauri1, P. Prabhakar2
1Population Council, HIV and AIDS Program, New Delhi, India, 2India HIV/AIDS Alliance, Regional Office, Hyderabad, India
|Predictors of impaired neurocognitive performance during follow-up among ART-naïve individuals initiating ART in ACTG clinical trials|
M. Smurzynski1, M. Yang1, K. Robertson2, A.C. Collier3, K. Wu1, R.J. Bosch1, R.J. Ellis4
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, United States, 2University of North Carolina, Neurology, Chapel Hill, United States, 3University of Washington, Harborview Medical Center, Medicine/Infectious Diseases, Seattle, United States, 4University of California, San Diego, Neurosciences, HIV Neurobehavioral Research Center, San Diego, United States
|Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients - Andrea Antinori|
|Determining the prevalence of HIV-associated neurocognitive disorder in a high-functioning and optimally treated Australian cohort: implications for international neuroHIV research - Lucette A. Cysique|
|Neurocognitive change in the era of HIV combination antiretroviral therapy: a longitudinal CHARTER study - Ronald J. Ellis|
|High ratios of circulating pro-inflammatory cytokines to anti-inflammatory IL-10 correlate with regional brain atrophy in chronic suppressed HIV infection - Kalpana Kallianpur|
|Is mental depression a serious issue among female sex workers? Evidence from Southern India - Sangram Kishor Patel|
|Predictors of impaired neurocognitive performance during follow-up among ART-naïve individuals initiating ART in ACTG clinical trials - Ronald J. Ellis|
Track B report by Silvia Nozza
In this session, speakers presented results of their studies
about neurocognitive disorders, inflammation and performance of ART in the neurological district.
Dr. A. Antinori presented a study on 1,020 people, that evaluated if
patients receiving an EFV-based regimen (N=324) had a worse neurocognitive
performance when compared to those currently receiving an ARV regimen not
including EFV (N=696). He showed that EFV exposure and
its duration were not associated with an increased risk of neurocognitive
Dr. L.A. Cysique explored the HAND prevalence in an Australian cohort of 90 HIV+ MSM, who have been compared to
49 HIV- donors. Rate of impairment was 53.3% in HIV+ patients, and 14.3% in HIV- individuals
(p<0.0001). Substantial proportion of HAND was present despite undetectable viral load.
Dr. I. Grant evaluated
the incidence and predictors of neurocognitive change over 35 (16-72) months in
436 participants in CHARTER study. Predictors of improvement occurred in 16.5%
of subject, and were education, absence of
depressive disorders, lower AST and switch to ART.
Dr. K. Kallianpur analyzed the levels of proinflammatory cytokines in 52 patients treated successfully with
ART, and showed that high circulating ratios to IL10 may mark brain atrophy independently of
age, nadir CD4 and intracranial volume.
Dr. S.K. Patel examined
high rate of mental depression in indian female sex workers, highligting that
the HIV prevention efforts with this population require a focus on addressing
the mental health issues.
Dr. R.J. Eliis evaluated prediction of impaired neurocognitive disorders in 1,626 non Hispanic
white and African-American naive patients initiating ART. Overall NPZ-3 scores
improved significantly over time (18.6% impaired at entry virus 14% at 4
years). Predictors of not improvement were IDU, stroke and HBV coinfection (HBsAg positive).